關於 cookie 的說明

本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗,我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示,便表示您已接受我們的網站使用條款。

Global Business NewsGlobal Business News

目前Global Business News文章數, 共 21016 篇 ,以下為 145 - 168 篇 訂閱此列表,掌握最新動態
Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO)

SAN FRANCISCO and SUZHOU, China, April 16, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announces the appointment of Dr. Nageatte Ibrahim, a world-famous Oncology Clinical Development Leader in the Pharmaceutical Industry, as the Oncology CMO. Dr. Ibrahim will provide the strategy, execution and leadership for the Oncology Global Clinical Development program. Dr. Nageatte Ibrahim has over 11 years of oncology industry drug development experience at Merck and GSK. Dr. Ibrahim also has 9 years of faculty appointments; an Instructor of Medicine at Harvard Medical School and attending physician at Dana-Farber Cancer Institute and later an Adjunct Assistant Professor at Perlman School of Medicine/Abramson Cancer Center.  Dr. Ibrahim's fore into industry began at GSK working on the dabrafenib/trametinib program and global approvals in melanoma. Prior to joining Innovent, Dr. Ibrahim was the Vice President, Global Clinical Development, Oncology at Merck, overseeing the strategy and execution for Keytruda and combinations across multiple tumor types and assets. In her early career at Merck, she led the pivotal global registration studies for Keytruda in front-line advanced melanoma and resectable melanoma which have been approved globally. Major accomplishments from Dr. Ibrahim's clinical development teams under her leadership include global approvals in Merkel cell, gastric, biliary, and hepatocellular cancers, resected Stage IIB or IIC melanoma, pediatric neurofibromatosis-1 (NF-1) as well as tumor agnostic indications for TMB-H expressing cancers and MSI-H/dMMR tumors. Dr. Ibrahim was also responsible for the development strategy of multiple assets, including in partnership with other companies, while at Merck. Dr. Ibrahim has a long and successful track record of building great teams, fostering an environment of learning and comradery, as well as mentoring and coaching future talent for leadership. She has also served as the Scientific Advisor for the Melanoma Research. Dr. Nageatte Ibrahim earned her B.S. in Molecular Biology and Biochemistry from Rutgers University and M.D. from MCP-Hahnemann/Drexel College of Medicine. Dr. Ibrahim completed an internal medicine residency at MCP-Hahnemann/Drexel College of Medicine, a Hematology and Oncology Fellowship from Tufts Medical Center, and Oncology Research Fellowship at Massachusetts General Hospital. Dr. Ibrahim possesses a Pennsylvania Medical License and ABIM Certification in Medical Oncology. "We are very excited to welcome Dr. Nageatte Ibrahim onboard as our Oncology CMO in Global Clinical Development," said Dr. Michael Yu, Founder, Chairman and CEO of Innovent. "Dr. Ibrahim has extensive experience in global clinical development in oncology along with excellent leadership skills. We believe that with Dr. Ibrahim joining Innovent, her talent and innovation will further enhance our clinical development capabilities in oncology, solidify our efforts in building a global clinical development platform and an international clinical team, develop a more innovative and cutting-edge pipeline with global First-in-Class and Best-in Class agents, and accelerate the innovation pace globally. Dr. Nageatte Ibrahim will bring new momentum to reach Innovent's goal 'to be one of the world's leading biopharmaceutical companies.'" "Innovent is a rapidly growing and cutting-edge biopharmaceutical company," said Dr. Ibrahim. "I am delighted to join such a company with a strong emphasis on science and innovation to bring new cancer treatments forward efficiently. There are many talented and passionate people at Innovent who strive to make great medicines that benefit patients around the world, and I am honored to join them in this quest." About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to provide high-quality biologics that are affordable to all. The company discovers, develops, manufactures and commercializes innovative medicines that treat some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has 10 products in the market, 3 new drug applications under the NMPA review, 5 assets in Phase III or pivotal clinical trials and 18 more molecules in early clinical stage. Innovent partners with over 30 global healthcare leaders, including Eli Lilly, Roche, Sanofi, Adimab, Incyte and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn. Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s). Forward-looking statement This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions. The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 308 加入收藏 :
TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation

FDA Fast Track designation granted for TLX101-CDx for glioma (brain cancer) imaging Collaboration agreement announced for joint development and commercialisation with UCSF PharmaLogic announced as commercial manufacturing and pharmacy distribution partner MELBOURNE, Australia, April 16, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has granted Fast Track designation[1] for the Company's investigational glioma imaging product, TLX101-CDx (Pixclara™[2], 18F-floretyrosine or 18F-FET). The granted Fast Track designation is for the characterisation of progressive or recurrent glioma using positron emission tomography (PET). Concurrently, Telix is in the final stages of preparing its U.S. New Drug Application (NDA) for TLX101-CDx in this initial indication, in both adult and paediatric patients. This designation enables expedited review and closer consultation with the FDA during the review process. Amino acid PET is currently included in U.S. and European guidelines for the imaging of gliomas[3], however there is no FDA-approved targeted PET agent for brain cancer imaging in the U.S. Telix's goal is to make this product commercially available in the U.S., significantly increasing patient access to this important imaging agent. Collaboration with the University of California, San Francisco Telix has an exclusive research collaboration and data license agreement with the University of California, San Francisco (UCSF). UCSF is one of the leading academic centres conducting clinical research into the use of FET PET[4] in a variety of neurological malignancies. This academic-industrial collaboration supporting joint development and commercialisation will enable Telix to offer TLX101-CDx access as a commercial product in the U.S., subject to regulatory approval. Thomas A. Hope, MD, Professor of Radiology at UCSF, said, "There is critical unmet need to improve the diagnosis and management of glioma, particularly in the post-treatment setting, and we are excited to leverage the clinical experience at UCSF to help make this investigational agent more widely available. 18F-FET has the potential to help determine if a glioma is truly progressing or undergoing a treatment-induced change, known as pseudo-progression, where MRI[5] – the standard of care – can often be inconclusive." David N. Cade, MD, Group Chief Medical Officer at Telix, stated, "This unique collaboration between Dr. Hope's team at UCSF and Telix will enable us to utilise our collective clinical data and expertise to facilitate nationwide access to FET PET in the United States while fostering ongoing research and development with the objective of expanding the clinical utility of this advanced imaging agent for the benefit of patients." Commercial Partnership: PharmaLogic Holdings Corp Telix has selected PharmaLogic Holdings Corp (PharmaLogic) as its commercial manufacturing and pharmacy distribution partner, to supply finished unit doses of TLX101-CDx to the U.S. market. Steven Chilinski, President and CEO at Pharmalogic, added, "Telix has quickly grown into a global theranostics leader with an impressive product pipeline. Through this partnership, we're delighted to bring this imaging agent to glioma patients in the U.S. upon regulatory approval."  Richard Valeix, Group Chief Commercial Officer at Telix, continued, "These milestones represent significant progress as we bring this investigational product closer to market in the U.S. and commercial launch. PharmaLogic has rapidly developed an excellent reputation for manufacturing radiopharmaceuticals to rigorous quality standards and will deliver a key component of Telix's supply chain strategy for TLX101-CDx in the U.S., subject to regulatory approval." About TLX101-CDx TLX101-CDx (Pixclara™[2]) is a PET imaging agent, which has been previously granted orphan drug designation (ODD) in the U.S. as an imaging agent for the management of glioma[6]. TLX101-CDx targets membrane transport proteins known as LAT1 and LAT2[7]. This enables TLX101-CDx to be potentially utilised as a companion diagnostic agent to TLX101 (4-L-[131I] iodo-phenylalanine, or 131I-IPA), Telix's LAT1-targeting investigational glioblastoma (GBM) therapy, currently under investigation in the and IPAX-2[8] and IPAX-Linz[9] studies. About gliomas in the U.S. Gliomas are very diffusely infiltrative tumours that affect the surrounding brain tissue. They are the most common form of central nervous system (CNS) neoplasm that originates from glial cells, accounting for approximately 30% of all brain and CNS tumours and 80% of all malignant brain tumours[10]. In the U.S., there are six cases of gliomas diagnosed per 100,000 people every year. GBM is a high-grade glioma and the most common and aggressive form of primary brain cancer, with approximately 22,000 new cases diagnosed annually in the U.S.[11]. The mainstay of treatment for GBM comprises surgical resection, followed by combined radiotherapy and chemotherapy. Despite such treatment, recurrence occurs in almost all patients[12], with an expected survival duration of 12-15 months from diagnosis[13]. About PharmaLogic   PharmaLogic is a world-class contract development and manufacturing organisation specialising in novel diagnostic imaging and therapeutic radiopharmaceuticals for the treatment of cancers and other malignancies. In addition to an established and reliable network of radiopharmacies, PharmaLogic has decades of expertise in drug development from discovery, through manufacturing and commercialisation. The Company seeks to take the lead in the advancement of radiopharmaceutical technology for the benefit of patients worldwide. For more information, visit: www.radiopharmacy.com.   About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). Telix's lead imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the FDA[14], by the Australian Therapeutic Goods Administration (TGA)[15], and by Health Canada[16]. No other Telix product has received a marketing authorisation in any jurisdiction. Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn. Telix Investor Relations Ms. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: kyahn.williamson@telixpharma.com This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board. Legal Notices The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. The information contained in this announcement is subject to change without notification. This announcement may contain forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical studies, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix's product candidates, if or when they have been approved; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the ASX or on our website. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future developments or a change in expectations or assumptions. ©2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals®, Illuccix® and Pixclara™2 names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. [1] Fast Track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier. More: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track. [2] Brand name subject to final regulatory approval. [3] Joint European Association of Nuclear Medicine//European Association of Neurooncology/Response Assessment in Neurooncology practice guidelines/Society for Nuclear Medicine and Molecular Imaging procedure standards for the clinical use of PET imaging in gliomas. [4] Positron emission tomography with 18F-floretyrosine. [5] Magnetic resonance imaging. [6] Telix ASX disclosure 6 October 2020. [7] Large amino acid transporters 1 and 2. [8] Telix media release 8 August 2023. ClinicalTrials.gov ID: NCT05450744. [9] Telix media release 22 November 2022. [10] Goodenberger et al. Cancer Genet. 2012. [11] Ostrom 2022, CBTRUS (Central Brain Tumor Registry of the United States) Statistical Report. [12] Park et al. Journal of Clinical Oncology. 2010. [13] Ostrom et al. Neuro Oncol. 2018. [14] Telix ASX disclosure 20 December 2021. [15] Telix ASX disclosure 2 November 2021. [16] Telix ASX disclosure 14 October 2022.  

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 262 加入收藏 :
【C.S】Cordyceps Sunshine has extended its market footprint in the world's largest traditional Chinese herbal medicine market with the introduction of their Cinnamomum product line.

TAIPEI, April 16, 2024 /PRNewswire/ -- Cordyceps Sunshine Group【C.S】Group, having recently achieved a successful U.S. IPO, hosted the '2024 China International Biomedical Innovation Development Conference and Chinese Rare Medicinal Herbs Cinnamomum Industry Transformation and Upgrade Conference' at the Academic Lecture Hall of the Oriental Hospital of Traditional Chinese Medicine, China Academy of Chinese Medical Sciences, in Beijing on January 20, 2024. The event saw participation from esteemed experts, and scholars spanning across Mainland China, Hong Kong, Macau, Taiwan, and national-level biomedical groups, traditional Chinese medicine technology, agricultural science, medical colleges, clinical medical research foundations, healthcare management institutions, research institutions, investment firms, totaling nearly 200 attendees. National Recognition for Ganoderma Industry for the First Time General Su Yuanfu, former Deputy Dean of the People's Liberation Army General Hospital, served as the Chairman of the Conference. The event was co-hosted by Professor Zhang Taojing, Chairman of the Academic Committee of the Conference and Vice Dean of the Oriental Hospital of Traditional Chinese Medicine at Beijing University of Chinese Medicine, and Researcher Zhang Haifeng, Director of the Sino-Foreign Traditional Medicine Exchange and Cooperation Center. The theme of the forum was "Biotechnology: Creating Value, Safeguarding Endangered Medicinal Resources, and Enhancing the Industry Chain." The discussions centered around the expansion and application of Taiwan's unique medicinal fungus - Cinnamomum, collectively exploring the Cinnamomum industry in the Greater China region. (Left)General Su Yuanfu, former Deputy Dean of the People's Liberation Army General Hospital; (Right)Professor Zhang Taojing, Vice Dean of the Oriental Hospital of Traditional Chinese Medicine at Beijing University of Chinese Medicine; (Down)The Deputy Chairman of the China International Biomedical Industry Association, strategic cooperation agreements were signed with the chairman Niu Xusheng of the Baoquan Agriculture and Technology. Academic Achievements Showcase in the Field of Cinnamomum During the conference, Liu Yanhong, Chief Technology Officer of 【C.S】Group, delivered a keynote speech on "The Origin and Development of Cinnamomum, Patent Technologies, and Crucial Components." Following this, experts and scholars from top agricultural science institutes, unique biological research and conservation centers, traditional Chinese medicine technology, Chinese medical science institutes, and innovation promotion organizations on both sides of the Taiwan Strait gave brilliant presentations on various topics, including "Establishing a Standard System to Aid the Green Development of the Cinnamomum Industry," "Application of Cinnamomum Industry Upgrading and Strain Improvement," "Pharmacological Applications and Prospects of Cinnamomum," "Chinese Rare Endangered Medicinal Herbs and Prevention and Treatment of Chronic Diseases," "Efficacy of Cinnamomum and its Application in Traditional Chinese Medical Practices," and "Promoting Youth Employment and Entrepreneurship through the Cinnamomum Industry." Industry Collaboration Expands Cinnamomum Market in Greater China At the conference, the Deputy Chairman of the China International Biomedical Industry Association, along with seven domestic and international experts in biopharmaceuticals and medical health, presented appointment letters to 【C.S】Group 's  Chief Technology Officer Liu Yanhong and others. Strategic cooperation agreements were signed with 10 partners from Hong Kong, Macau, and Taiwan. Baoquan Agriculture and Technology was appointed as the exclusive supplier of raw materials for Cinnamomum. Plans were outlined for promoting "financial resources to drive technological innovation and green development in the Cinnamomum industry" and "establishing the Cinnamomum industry supply chain." The raw materials of Cinnamomum will be: Tested for medicinal and edible origin by Beijing University of Chinese Medicine. Initially introduced to the market in the form of medicinal diets with the assistance of relevant units, including the National Health Commission. Used in a health management intervention program for 3,000 retired senior veterans nationwide, initiated by the National Health Commission, with ongoing tracking of cancer and cardiovascular and cerebrovascular disease rates. Deep collaboration with national-level channels such as Beijing Tongrentang and China National Pharmaceutical Group, expediting the construction of the industrial system for Cinnamomum and increasing its market share in the Greater China region. 【C.S】Group Commands Discourse Power in the Greater China Region for Cinnamomum Baoquan Agriculture and Technology has established the first Cinnamomum cultivation and production demonstration base in Shunde, Guangdong. The Cinnamomum Conference held in Beijing represents the highest level of collaboration in industry history. It asserts 【C.S】Group 's influential position in the Greater China Cinnamomum industry. Significant annual revenue growth is expected, with positive implications for future stock performance. The group is positioned to emerge as an international unicorn enterprise in the medicinal herbs sector. Within the next 12-18 months, plans are underway for a Nasdaq uplisting, signaling promising prospects on the horizon.

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 303 加入收藏 :
China Liberal Education Holdings Limited Reports Financial Results for Fiscal Year 2023

BEIJING, April 16, 2024 /PRNewswire/ -- China Liberal Education Holdings Limited (Nasdaq: CLEU) ("China Liberal", the "Company", "we", "our", or "us"), a China-based company that provides technological consulting services for smart campus solutions and other educational services, today announced its audited financial results for the fiscal year ended December 31, 2023. Ms. Ngai Ngai Lam, Chairwoman and CEO of China Liberal, commented, "Our revenue experienced a decline in fiscal year 2023 due to termination of education programs offered by joint ventures of the PRC and foreign institutions ("Sino-foreign Jointly Managed Academic Programs"), but we still managed to maintain a relatively high gross margin level at around 57.1% during the fiscal year. Despite the major business restructuring under way, it is worth noting that our existing business has witnessed a rapid growth, with the revenue from tailored job readiness training services and technological consulting services for smart campus solutions surging by 74.2% and 144.5%, respectively, compared to fiscal year 2022. Meanwhile, our total cash had risen substantially to $20.34 million as of December 31, 2023. These solid data showcase the resilience of our business model and operation which is moving in the right direction. Looking ahead, we will strive to keep the current momentum, expand our partnerships, and develop new growth drivers, with the goal of generating greater profits for our shareholders. Service quality is at the core of our journey for long-term development, which we believe will continue to push us forward for faster growth." Fiscal Year 2023 Financial Highlights For the Years Ended December 31, ($ millions, except for percentages or per share data) 2023 2022 %Change Revenue 2.89 5.22 (44.7 %) Gross profit 1.65 4.03 (59.1 %) Gross margin 57.1 % 77.2 % (20.1pp) Loss from operations (0.93) (1.55) 40.0 % Net loss (4.96) (1.69) (193.6 %) Basic and diluted loss per share (1.65) (1.94) 14.9 % Note: pp represents percentage points. Revenue was $2.89 million for fiscal year 2023, compared to $5.22 million for fiscal year 2022. Gross profit was $1.65 million for fiscal year 2023, compared to $4.03 million for fiscal year 2022. Gross margins were 57.1% and 77.2% for fiscal year 2023 and 2022, respectively. Loss from operations was $0.93 million for fiscal year 2023, compared to $1.55 million for fiscal year 2022. Net loss was $4.96 million for fiscal year 2023, compared to $1.69 million for fiscal year 2022. Basic and diluted loss per share were $1.65 for fiscal year 2023, compared to $1.94 for fiscal year 2022. Fiscal Year 2023 Financial Results Revenue Revenue decreased by $2.33 million, or 44.7%, to $2.89 million for fiscal year 2023 from $5.22 million for fiscal year 2022. The decrease in our revenue was mainly attributable to the discontinued revenue from Sino-foreign Jointly Managed Academic Programs as this service was terminated after disposal of colleges in December 2023. The Company did not generate revenue from Sino-foreign Jointly Managed Academic Programs for fiscal year 2023. Revenue from Sino-foreign Jointly Managed Academic Programs was $3.34 million for fiscal year 2022. This decrease was primarily attributable to two factors (i) revenue generated from Sino-foreign Jointly Managed Academic Programs were accounted for as transactions between Wanwang Investment Limited ("Wanwang") and China Liberal (Beijing) Education Technology Co., Ltd. ("China Liberal Beijing") and were eliminated upon consolidation, and (ii) the termination of this line of service after disposition of two colleges in 2023. Revenue from tailored job readiness training services increased by $0.94 million, or 74.2%, to $2.20 million for fiscal year 2023, from $1.26 million for fiscal year 2022, mainly attributable to revenue contribution from our newly acquired entity, Oriental Wisdom Cultural Development Co., Ltd. ("Oriental Wisdom") in July 2022. Oriental Wisdom contributed only five months of revenue in 2022, as opposed to 12 months of revenue in 2023. On July 14, 2022, the Company closed the transactions contemplated by the stock purchase agreement entered into on June 9, 2022 by and among the Company, China Liberal Beijing, Oriental Wisdom, the acquired company, and Beijing Cloud Class Technology Co., Ltd., the seller of the acquired company, and completed its acquisition of Oriental Wisdom, an integrated education services provider focusing on operating jointly-managed academic programs in the vocational higher education industry in China. The Company did not generate revenue from Overseas Study Consulting Services for fiscal year 2023. Revenue from Overseas Study Consulting Services was $0.32 million for fiscal year 2022. We discontinued our Overseas Study Consulting Services in January 2023 after all existing contracts with Beijing Foreign Studies University came to completion and all existing performance obligations were satisfied, in accordance with the administration guidelines issued by General Office of the Ministry of Education in December 2021, which provide that universities and colleges shall cease projects and cooperation with external parties. Revenue from smart campus related technological consulting services and technical support services for other entities increased by $0.40 million, or 144.5%, to $0.68 million for fiscal year 2023, from $0.28 million for fiscal year 2022. The increase was primarily attributable to an increase of projects undertaken from six projects in 2022 to seven projects in 2023. The increase in revenue was also attributable to the increase in average project size from $46,563 per project in 2022, to $97,579 per project in 2023. The Company did not generate revenue from textbooks and course material sales for fiscal year 2023. Revenue from textbooks and course material sales was $13,948 for fiscal year 2022. The decrease was mainly attributable to decreased demand for our textbooks and course materials. According to our agreement with the publisher, we will be able to receive a fee only when the number of copies printed by the publisher exceed a pre-determined volume of 5,100 copies. In 2023, 24,841 copies were printed. Cost of Revenue Cost of revenue increased by $0.05 million, or 4.3%, to $1.24 million for fiscal year 2023, from $1.18 million for fiscal year 2022. The increase was primarily due to the increase in cost of revenue associated with tailored job readiness training services by $0.3 million and cost of revenue associated with technological consulting services for smart campus related projects by $0.3 million. The increase was partially offset by a decrease of cost of revenue associated with Sino-foreign jointly managed academic programs by $0.5 million and cost of revenue associated with overseas study consulting services by $0.1 million. Gross Profit Gross profit decreased by $2.38 million, or 59.1%, to $1.65 million in fiscal year 2023, from $4.03 million in fiscal year 2022, while gross profit margin decreased by 20.1%, to 57.1% for fiscal year 2023, from 77.2% for fiscal year 2022. The decrease in gross profit was primarily due to decreased gross profit contribution of $2.9 million from Sino-foreign Jointly Managed Academic Programs and gross contribution of $0.2 million from overseas study consulting services. The decrease was partially offset by increased gross profit contribution of $0.6 million from tailored job readiness training services and gross profit contribution of $0.1 million from technological consulting services for smart campus. Operating Expenses Selling expenses decreased by $0.05 million, or 18.4%, to $0.23 million for fiscal year 2023, from $0.28 million for the fiscal year 2022. The decrease in selling expenses was primarily attributable to a reduction of headcount in our sales and marketing force and related travelling expenses. General and administrative expenses decreased by $1.88 million, or 41.2%, to $2.68 million for the fiscal year 2023, from $4.57 million for the fiscal year 2022, primarily due to decreased in share-based compensation of $2.8 million. The decrease was partially offset by an increase in staff salaries and related benefit expenses of $0.9 million due to full year impact of Oriental Wisdom staff expenses in 2023 as compared to six months impact in 2022 as Oriental Wisdom was newly acquired in June 2022. Interest Expenses Interest expenses increased by $0.15 million, or 112.1%, to $0.29 million for fiscal year 2023 from $0.14 million for fiscal year 2022, primarily due to interest expenses on short-term bank loan, loans from third parties and loans from related parties. Other Income (Expense) Other income was $0.12 million for fiscal year 2023, as compared to other expenses of $0.15 million for fiscal year 2022. Other income related to forfeiture of advance from a supplier of $0.1 million due to project cancellation. Other expenses in 2022 related to miscellaneous non-operating expenses incurred in 2022. Income Tax Expenses Income tax expenses were $1,973 and $0.46 million for fiscal year 2023 and fiscal year 2022, respectively. The decrease in income tax expenses was due to a net loss incurred by the Company and its subsidiaries. Net Loss Net loss was $4.96 million for fiscal year 2023, compared to a net loss of $1.69 million for fiscal year 2022. Basic and diluted loss per share were $1.65 for fiscal year 2023, compared to basic and diluted loss per share of $1.94 for fiscal year 2022. Financial Condition As of December 31, 2023, the Company had cash of $20.34 million, compared to $12.12 million as of December 31, 2022. Net cash used in operating activities was $3.78 million for fiscal year 2023, compared to net cash provided by operating activities of $0.42 million for fiscal year 2022. Net cash used in investing activities was $2.24 million for fiscal year 2023, compared to $32.55 million for fiscal year 2022. Net cash provided by financing activities was $12.72 million for fiscal year 2023, compared to $12.90 million for fiscal year 2022. Recent Development On December 28, 2023, the Company entered into a share transfer agreement (the "Share Transfer Agreement") with Wanwang and Xiaoshi Huang, pursuant to which the Company agreed to transfer all of the equity interests in Wanwang to Xiaoshi Huang in consideration for US$40 million. Xiaoshi Huang also agreed to unconditionally and irrevocably release and discharge the Company and all of the Company's related parties from any and all claims, debts, obligations and liabilities arising from or in connection with the Contingent Payments under the Stock Purchase Agreement. Additionally, parties to the Share Transfer Agreement agreed that the results of operations of Wanwang from the closing of the transactions contemplated by the Stock Purchase Agreement up to August 31, 2023 shall be consolidated into the Company's results of operations, and since September 1, 2023, results of operations of Wanwang and any income or losses incurred by Wanwang shall be borne by Xiaoshi Huang. The Company expects the transactions to close on or before June 30, 2024. About China Liberal Education Holdings Limited China Liberal is an educational services provider headquartered in Beijing, China. China Liberal provides a wide range of services, including technological consulting for Chinese universities to improve their campus information and data management systems, designed to enhance the teaching, operating, and management environment of the universities, thus establishing a "smart campus." Additionally, China Liberal offers tailored job readiness training for graduating students. For more information, please visit the Company's website at http://ir.chinaliberal.com/. Forward-Looking Statements This document contains forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's expectations and projections about future events, which the Company derives from the information currently available to the Company. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those using terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. When evaluating these forward-looking statements, you should consider various factors, including our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as required by law. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can provide no assurance that these expectations will prove to be accurate, and it cautions investors that actual results may differ materially from the anticipated results. Investors are encouraged to review the risk factors that may affect future results in the Company's registration statement and in its other filings with the U.S. Securities and Exchange Commission. Investor Relations ContactChina Liberal Education Holdings LimitedEmail: ir@chinaliberal.com Ascent Investor Relations LLCTina XiaoPresidentPhone: +1 646-932-7242Email: investors@ascent-ir.com     CHINA LIBERAL EDUCATION HOLDINGS LIMITED CONSOLIDATED BALANCE SHEETS  As of   As of   December 31,  December 31, 2023 2022 ASSETS CURRENT ASSETS Cash $ 20,337,847 $ 12,121,824 Account receivables, net 1,453,230 954,603 Advance to suppliers 3,521,176 - Inventories, net 167,493 193,738 Prepaid expenses and other current assets, net 114,732 122,407 Receivable from disposal of subsidiaries 40,000,000 - Current assets from discontinued operations - 5,018,865 TOTAL CURRENT ASSETS $ 65,594,478 $ 18,411,437 NON-CURRENT ASSETS Goodwill on acquisitions 6,747,543 9,481,547 Property and equipment, net 5,157 19,785 Intangible assets, net 351,680 423,272 Right-of-use assets 102,509 13,107 Non-current assets from discontinued operations - 75,639,404 TOTAL NON-CURRENT ASSETS $ 7,206,889 $ 85,577,115 TOTAL ASSETS $ 72,801,367 $ 103,988,552 LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES Account payables $ 571,432 $ 762,366 Contract liabilities 212,473 251,368 Short-term bank loan 32,191 20,784 Taxes payable 1,438,658 1,346,992 Due to related parties 1,395,225 390,550 Lease liabilities 63,410 10,887 Loans from third parties 1,589,702 975,716 Accrued expenses and other current liabilities 928,816 1,869,946 Current liabilities from discontinued operations - 14,359,841 TOTAL CURRENT LIABILITIES $ 6,231,907 $ 19,988,450 NON-CURRENT LIABILITIES Lease liabilities 32,525 - Non-current liabilities from discontinued operations - 21,515,801 TOTAL LIABILITIES $ 6,264,432 $ 41,504,251 COMMITMENTS AND CONTINGENCIES SHAREHOLDERS' EQUITY Ordinary shares, $0.015 par value, 7.5 million shares authorized, 3,351,336 and 2,151,336 shares issued and outstanding at December 31, 2023 and 2022, respectively* $ 5,028 $ 3,228 Additional paid-in capital* 72,142,580 63,219,380 Statutory reserve 1,006,384 1,006,384 Accumulated deficits (6,786,949) (1,828,205) Accumulated other comprehensive income 169,892 83,514 Total shareholders' equity $ 66,536,935 $ 62,484,301 TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 72,801,367 $ 103,988,552 * Retrospectively restated for effect of share re-designation on November 30, 2023 and 1-for-15 reverse share split on January 19, 2024.     CHINA LIBERAL EDUCATION HOLDINGS LIMITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) For the years ended December 31, 2023 2022 2021 REVENUE $ 2,886,222 $ 5,218,283 $ 3,909,546 COST OF REVENUE (1,235,370) (1,184,185) (1,149,148) GROSS PROFIT 1,650,852 4,034,098 2,760,398 OPERATING EXPENSES Allowance for doubtful accounts 329,589 (734,750) - Selling expenses (230,061) (282,099) (152,759) General and administrative expenses (2,684,903) (4,566,187) (3,778,329) Total operating expenses (2,585,375) (5,583,036) (3,931,088) LOSS FROM OPERATIONS (934,523) (1,548,938) (1,170,690) OTHER (EXPENSES) INCOME Goodwill impairment (2,734,004) - - Interest income 2,043 10,155 94,195 Interest expenses (289,677) (136,588) (3,145) Government subsidy income 11,254 6,887 - Other income, net 122,828 (149,728) 129,793 Total other (expenses) income, net (2,887,556) (269,274) 220,843 Loss before income taxes (3,822,079) (1,818,212) (949,847) Income tax expenses (1,973) (460,040) (300,034) Net loss from continuing operations $ (3,824,052) $ (2,278,252) $ (1,249,881) Discontinued operations Net (loss) income from discontinued operations, net of tax (1,134,692) 589,349 - Net loss $ (4,958,744) $ (1,688,903) $ (1,249,881) COMPREHENSIVE INCOME (LOSS) Total currency translation differences arising fromconsolidation 86,378 (307,633) 232,001 TOTAL COMPREHENSIVE LOSS $ (4,872,366) $ (1,996,536) $ (1,017,880) Loss per share Basic and diluted $ (1.65) $ (1.94) $ (1.81) Weighted average number of shares outstanding Basic and diluted 2,321,643 1,175,156 691,238 * Retrospectively restated for effect of share re-designation on November 30, 2023 and 1-for-15 reverse share split on January 19, 2024.     CHINA LIBERAL EDUCATION HOLDINGS LIMITED CONSOLIDATED STATEMENTS OF CASH FLOWS For the years ended December 31, 2023 2022 2021 Cash flows from operating activities Net loss $ (4,958,744) $ (1,688,903) $ (1,249,881) Net (loss) income from discontinued operations $ (1,134,692) $ 589,349 - Net loss from continuing operations $ (3,824,052) $ (2,278,252) $ (1,249,881) Adjustments to reconcile net loss to net cash (used in) provided by operating activities: Allowance for accounts receivable (413,669) 611,819 - Allowance for inventory 18,975 5,392 1,101 Allowance for prepaid expenses and other currentassets 65,105 122,930 - Depreciation of property and equipment 10,657 47,056 18,652 Amortization of intangible assets 63,111 32,365 - Loss on disposal of subsidiaries 2,285,309 - - Non-cash lease expenses 37,399 86,911 91,386 Loss from disposal of property and equipment - - 607 Share-based compensation - 2,832,500 2,288,251 Goodwill impairment 2,734,004 - - Changes in operating assets and liabilities: Accounts receivable, net 3,560,308 1,416,032 (1,504,828) Contract receivable, net - 1,898,236 2,781,603 Advance to suppliers (3,530,625) 4,262,151 (4,355,926) Inventories net 1,794 (13,760) (9,469) Prepaid expenses and other current assets (60,837) (54,548) 33,653 Accounts payable (169,622) (400,750) 40,239 Contract liabilities (974,788) 654,742 462,253 Taxes payable 130,472 642,372 90,150 Lease liabilities (41,829) 97,222 (67,754) Accrued expenses and other current liabilities (272,172) 35,656 (40,842) Net cash provided by (used in) operating activities from continuing operations (380,460) 9,998,074 (1,420,805) Net cash used in operating activities from discontinued operations (3,404,155) (9,574,477) - Net cash (used in) provided by operating activities (3,784,615) 423,597 (1,420,805) Cash flows from investing activities Purchase of property and equipment - - (4,439) Prepayment for acquisitions - - (1,474,217) Acquisitions of subsidiaries, net of cash - (31,938,273) - Disposal of subsidiaries, net of cash (2,173,659) - - Repayment of advance from related parties - - 1,471,113 Net cash used in investing activities fromcontinuing operations (2,173,659) (31,938,273) (7,543) Net cash used in investing activities fromdiscontinued operations (63,930) (612,955) - Net cash used in investing activities (2,237,589) (32,551,228) (7,543) Cash flows from financing activities Proceeds from advance from a related party 320,041 - 9,415 Proceeds from loans from third parties 1,336,837 996,610 - Repayment of loans from third parties (313,177) - - Repayment of due to a related party - (91,308) - Proceeds from short-term bank loans 26,155 - - Net proceeds from issuance of ordinary shares 8,925,000 11,989,949 29,047,088 Net cash provided by financing activities from continuing operations 10,294,856 12,895,251 29,056,503 Net cash provided by financing activities from discontinued operations 2,422,573 - - Net cash provided by financing activities 12,717,429 12,895,251 29,056,503 Effect of changes of foreign exchange rates on cash (7,449) 204,030 34,250 Net increase (decrease) in cash 6,687,776 (19,028,350) 27,662,405 Cash, beginning of year 13,650,071 32,678,421 5,007,449 Cash, end of year $ 20,337,847 $ 13,650,071 $ 32,678,421 Reconciliation of cash, beginning of year Cash from continuing operations $ 12,121,824 $ 32,678,421 $ 5,007,449 Cash from discontinued operations 1,528,247 - - Cash, beginning of year $ 13,650,071 $ 32,678,421 $ 5,007,449 Reconciliation of cash, end of year Cash from continuing operations $ 20,337,847 $ 12,121,824 $ 32,678,421 Cash from discontinued operations - 1,528,247 - Cash, end of year $ 20,337,847 $ 13,650,071 $ 32,678,421 Supplemental disclosure of cash flow information: Cash paid for interest expense $ 2,648 $ 2,399 $ 40,555 Cash paid for income tax - - - Supplemental disclosure of non-cash investing and financing activities Right-of-use assets obtained in exchange for operating lease obligations $ 61,988 - - Acquisition in the form of shares - $ 7,700,000 -    

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 272 加入收藏 :
Moatable Announced Resignation of Director

PHOENIX, April 16, 2024 /PRNewswire/ -- Moatable, Inc. (OTC Pink: MTBLY) ("Moatable" or the "Company"), which operates two US-based SaaS businesses, Lofty Inc.© and Trucker Path Inc.©, today announced that Mr. James Reed resigned from the Company's Board of Directors, effective on April 12, 2024. Mr. Reed resigned for personal reasons and not due to any disagreement with the Company on any matter relating to the Company's operations, policies or practices. "On behalf of the Board of Directors, I would like to express my gratitude to Mr. Reed for his time and valuable contribution to Moatable over the past year," said Moatable's Chairman and Chief Executive Officer, Mr. Joseph Chen. About Moatable Inc. Moatable, Inc. (OTC Pink: MTBLY) operates several US-based SaaS businesses including Lofty and Trucker Path. Moatable's American depositary shares, each of which currently represents forty-five Class A ordinary shares, trade on OTC Pink open market under the symbol "MTBLY". Forward-Looking Statements This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Statements that are not historical facts, including statements about Moatable's beliefs and expectations, including statements on making investments and operating businesses that generate long-term returns for investors, and expectations for future growth and innovation are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Moatable's goals and strategies; Moatable's future business development, financial condition and results of operations; Moatable's expectations regarding demand for and market acceptance of its services; Moatable's plans to enhance user experience, infrastructure and service offerings. Further information regarding these and other risks is included in our annual report on Form 10-K for the year ended December 31, 2022 and other documents filed with the SEC. All information provided in this press release is as of the date of this press release, and Moatable does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 243 加入收藏 :
Appian Signs a Strategic Collaboration Agreement with AWS to Deliver Private AI for End-to-End Process Automation

Collaboration leverages Amazon Bedrock and Sagemaker to power Appian's Data Fabric with generative AI capabilities MCLEAN, Va., April 16, 2024 /PRNewswire/ -- Appian (Nasdaq: APPN) announced today that it has signed a Strategic Collaboration Agreement (SCA) with Amazon Web Services (AWS) to make generative artificial intelligence (AI) more accessible to enterprise business processes. Appian will invest significant resources to find novel ways to combine Appian's native AI capabilities and the Appian data fabric with the large language models (LLMs) provided by Amazon Bedrock and machine learning (ML) capabilities from Amazon SageMaker. Amazon Bedrock is a fully managed service that offers a choice of high-performing foundation models (FMs) from leading AI companies via a single API, along with a broad set of capabilities organizations need to build generative AI applications with security, privacy, and responsible AI. Amazon SageMaker is a service to build, train, and deploy ML models for any use case with fully managed infrastructure, tools, and workflows. Appian announces that it has signed a Strategic Collaboration Agreement (SCA) with Amazon Web Services (AWS) to make generative artificial intelligence (AI) more accessible to enterprise business processes. Appian is designed to automate mission-critical business processes in some of the most innovative, highly regulated, and security-sensitive industries. These customers want to leverage AI while maintaining the security of their data. They also face shortages of data scientists and increasing information technology (IT) backlogs. Appian's private AI approach gives enterprises control over their own data and makes sure their data is not used to train public models that other organizations can use. Appian's low-code AI process platform with its Appian AI Skills capability enables customers to easily incorporate AI into business processes, letting AI and humans work together seamlessly. "Appian's collaboration with AWS takes a major leap forward with this announcement," said Michael Beckley, CTO at Appian. "The AI economy is here and it will quickly create a strong competitive advantage for organizations that know how to use it. Enterprises that upgrade their core business processes with AI and Appian's data-driven insights will thrive while those that fail to do so will lose control of their data and their future. Amazon Bedrock is an important enabler for our private AI vision. Together, we give organizations the ability to effortlessly use AI for process automation with data privacy and security at the forefront." "The Appian AI Skill Designer helps us get real value from AI without needing a team of data scientists to figure it out. The no-code design made it quick and easy for our developers to incorporate AI into our existing applications," said Matt Richard, CIO at LiUNA. By harnessing the capabilities of Amazon Bedrock, Appian gains the ability to host LLMs within customer compliance boundaries and privately customize those models, ensuring that sensitive data remains secure and confidential. Amazon SageMaker allows Appian customers to create, train, and fine tune proprietary AI models using their own data. As AWS AI and ML services are designed with security and privacy best practices, Appian customers can leverage their data to receive more accurate and relevant results from their generative AI applications based on the unique needs of their businesses. "Companies deeply care about security and privacy, especially when leveraging AI. This collaboration between AWS and Appian helps customers streamline mission-critical business processes confidently by leveraging AI and machine learning in a secure and compliant manner," said Chris Grusz, Managing Director of Technology Partnerships at AWS. Learn more about Appian's relationship with AWS and its vision for generative AI-powered developer experiences. About AppianAppian is a software company that automates business processes. The Appian AI Process Platform includes everything you need to design, automate, and optimize even the most complex processes, from start to finish. The world's most innovative organizations trust Appian to improve their workflows, unify data, and optimize operations—resulting in better growth and superior customer experiences. For more information, visit appian.com. [Nasdaq: APPN] Follow Appian: LinkedIn, Twitter. Photo - https://mma.prnasia.com/media2/2386068/9005107_DGR_Appian_AWS_AI_Press_Release_image_v3_01__1.jpg?p=medium600 Logo - https://mma.prnasia.com/media2/1948800/Appian_400px_Blank_Logo.jpg?p=medium600

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 333 加入收藏 :
首 頁 我的收藏 搜 尋 新聞發佈